Lorbrena

Nuvalent races to FDA to challenge Pfizer for lung cancer market

Nuvalent has reported phase 1/2 lung cancer data, teeing up talks about a filing that could establish neladalkib as a challenger to Pfizer’s Lorbrena.

Nick Paul Taylor Nov 17, 2025 7:45am